Ozempic review: is it worth it?
Ozempic is semaglutide approved for type 2 diabetes. Often prescribed off-label for weight loss.
Status update: Stopping Ozempic for T2D causes A1C rebound within 2-4 weeks. Weight regain expected. Always discuss tapering with prescriber — sudden discontinuation can destabilize glycemic control.
On this page
A proven diabetes drug, not a weight-loss shortcut
A proven diabetes drug, not a weight-loss shortcut
For adults with type 2 diabetes, Ozempic is one of the most well-supported options available: it reliably lowers blood sugar, has shown cardiovascular and kidney benefits in high-risk patients, and produces modest weight loss as a secondary effect. But it is FDA-approved for diabetes (plus cardiovascular and kidney risk reduction in qualifying patients), not for obesity, so using it solely for weight loss is off-label, and people in that situation should ask their doctor about Wegovy, which contains the same molecule at a higher dose and is approved for weight management. Expect real, usually manageable GI side effects and a high list price.
- May be covered by insurance
We may earn a commission if you buy through this link, at no extra cost to you. It never affects our score. How we make money
- Personal or family history of medullary thyroid carcinoma (MTC). Ozempic is contraindicated in these patients (FDA Boxed Warning / Section 4). Semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors in rodents; human relevance is undetermined.
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Ozempic is contraindicated in patients with MEN 2 (FDA Boxed Warning / Section 4).
- Prior serious hypersensitivity reaction to semaglutide or to any of the excipients in Ozempic. Serious reactions including anaphylaxis and angioedema have been reported (FDA Section 4).
- Not a substitute for insulin and not indicated in type 1 diabetes mellitus; semaglutide has not been studied and should not be used to treat type 1 diabetes or diabetic ketoacidosis (FDA label / StatPearls). Note: this is a limitation of use rather than a labeled absolute contraindication.
- Pregnancy: not an absolute FDA contraindication but should be discontinued/avoided. Animal reproduction studies show potential fetal harm; the label advises use during pregnancy only if potential benefit justifies the potential risk, and Ozempic should be discontinued at least 2 months before a planned pregnancy due to its long half-life.
- Strong, well-documented blood-sugar control, lowering A1C by roughly 1 to 2 percentage points in trials
- Reduced the combined rate of major cardiovascular events (heart attack, stroke, CV death) by 26% in high-risk patients in the SUSTAIN-6 trial, driven mainly by fewer strokes
- Newly FDA-approved (January 2025, based on the FLOW trial) to reduce the risk of worsening kidney disease in type 2 diabetes with chronic kidney disease, the broadest indication in its class
- Convenient once-weekly injection rather than daily dosing, with modest weight loss as a secondary benefit
- Backed by an extensive, multi-trial clinical evidence base and years of real-world use
- Frequent gastrointestinal side effects, including nausea, vomiting, and diarrhea, especially when starting or increasing the dose
- Not FDA-approved for weight loss alone, so using it solely to lose weight is off-label and usually not covered by insurance
- High cost, with a list price around $935/month and retail cash prices near $935-$969/month without insurance, and coverage gaps are common
- Carries a boxed warning for thyroid C-cell tumors and is contraindicated in people with a personal or family history of medullary thyroid cancer or MEN 2; SUSTAIN-6 also reported more diabetic retinopathy complications
- Requires ongoing weekly injections, and benefits (including weight loss and blood-sugar control) tend to reverse if you stop taking it
In-depth review
What is Ozempic and what is it FDA-approved for?
Ozempic is the brand name for semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist made by Novo Nordisk and delivered as a once-weekly subcutaneous injection from a prefilled pen. The FDA first approved it in December 2017.
Its approved indications are narrower than its reputation suggests. Per the FDA label, Ozempic is indicated, as an adjunct to diet and exercise, to:
- Improve glycemic control in adults with type 2 diabetes mellitus (its core, original use).
- Reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal heart attack, nonfatal stroke) in adults with type 2 diabetes *and* established cardiovascular disease.
- Reduce the risk of kidney disease progression, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease — an indication added in 2025 on the strength of the FLOW trial (FDA; NEJM 2024).
Critically, Ozempic is not FDA-approved for weight loss or for obesity (FDA). It is not approved for use in type 1 diabetes. The same molecule, semaglutide, is sold as Wegovy at higher doses (up to 2.4 mg) with an explicit weight-management indication, and as Rybelsus in an oral tablet form for type 2 diabetes. The widespread use of Ozempic specifically for weight loss is off-label prescribing — common, often effective, but outside the FDA-reviewed indication.
How does Ozempic (semaglutide) work?
Semaglutide mimics GLP-1, a natural incretin hormone the gut releases after eating. By activating GLP-1 receptors, it works through several complementary mechanisms (NIH/StatPearls):
- Glucose-dependent insulin secretion. It prompts the pancreas to release more insulin — but only when blood glucose is elevated. This glucose-dependence is why semaglutide alone carries a low intrinsic risk of hypoglycemia.
- Glucagon suppression. It reduces secretion of glucagon, the hormone that tells the liver to dump glucose into the blood.
- Slowed gastric emptying. Food leaves the stomach more slowly, blunting post-meal glucose spikes and prolonging fullness.
- Central appetite regulation. It acts on appetite centers in the brain to reduce hunger and increase satiety — the mechanism behind the weight loss seen as a secondary effect.
The "semaglutide" molecule is engineered for a long half-life (around one week), which is what makes once-weekly dosing possible — a meaningful convenience advantage over older daily GLP-1s such as liraglutide.
How well does Ozempic work? What the trials show
Ozempic's evidence base — the global SUSTAIN phase 3 program plus dedicated outcomes trials — is one of the most mature in the GLP-1 class.
Blood sugar (A1c)
Across the SUSTAIN trials, semaglutide produced A1c reductions of roughly 1.0% to 1.8%, varying by dose and the comparator. In Novo Nordisk's labeling, the majority of patients on the 1 mg dose reached the American Diabetes Association target of A1c below 7%. The higher 2 mg dose, approved in 2022, delivered modestly greater A1c reduction than 1 mg (FDA; PRNewswire 2022). In head-to-head trials, semaglutide generally outperformed other injectable GLP-1s such as dulaglutide on glucose lowering.
Weight
Although not a weight-loss drug on label, Ozempic consistently produced clinically meaningful weight reduction as a secondary outcome in SUSTAIN — typically on the order of several kilograms, more than older diabetes drugs. This is less than the weight loss seen with Wegovy (semaglutide 2.4 mg), which is dosed and studied specifically for that purpose. If weight loss is the primary goal, the on-label, higher-dose product exists for a reason.
Cardiovascular outcomes
This is where Ozempic moved from "good glucose drug" to standard-of-care. In SUSTAIN-6, a double-blind trial of 3,297 patients with type 2 diabetes at high cardiovascular risk, semaglutide reduced the composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke by 26% versus placebo (hazard ratio 0.74) over a median 2.1 years (Marso SP et al., NEJM 2016;375:1834-1844; PMID 27633186). That result underpins the FDA cardiovascular-risk-reduction indication.
Kidney outcomes
In the FLOW trial (3,533 adults with type 2 diabetes and chronic kidney disease), once-weekly semaglutide 1 mg reduced the risk of major kidney outcomes — a composite including kidney failure, a 50% drop in eGFR, and kidney/cardiovascular death — by 24% versus placebo (NEJM 2024; NCT03819153). FLOW also showed lower risk of cardiovascular events and all-cause death. The trial was stopped early for efficacy and led to the 2025 kidney indication.
Honest caveat: these are relative risk reductions in defined high-risk populations. Absolute benefits are smaller, and individual results — especially for weight — vary widely. The trials enrolled people with diabetes; the cardiovascular and kidney findings should not be assumed to transfer wholesale to people without diabetes taking the drug off-label.
Dosing and titration
Ozempic is titrated slowly to limit gastrointestinal side effects (FDA label):
- Weeks 1–4: 0.25 mg once weekly. This starting dose is a *titration* dose, not a therapeutic one — it does little for blood sugar and exists only to let the gut adapt.
- Weeks 5–8: increase to 0.5 mg once weekly.
- If further control is needed: increase to 1 mg once weekly after at least 4 weeks at 0.5 mg.
- Maximum: 2 mg once weekly, if needed after at least 4 weeks at 1 mg.
It is injected subcutaneously in the abdomen, thigh, or upper arm, on the same day each week, with or without food. Doses can be given at any time of day. If a dose is missed, it can be taken within 5 days; otherwise it is skipped. Rushing the titration is the most common avoidable cause of intolerable nausea.
Side effects, warnings, and contraindications
Boxed warning
Ozempic carries an FDA boxed warning for thyroid C-cell tumors: semaglutide caused dose- and duration-dependent thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in rodents. Whether this risk applies to humans is unknown (FDA). It is contraindicated in anyone with a personal or family history of MTC, or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Most common side effects
The most common adverse reactions are gastrointestinal — nausea, vomiting, diarrhea, abdominal pain, and constipation. Nausea is the most frequent, affecting roughly one in five patients in trials, and GI symptoms are the leading reason people discontinue (FDA; NIH). These are usually dose-related and tend to ease over weeks as the body adapts, which is the rationale for slow titration.
Serious warnings
The label flags several less common but important risks (FDA):
- Pancreatitis — stop the drug and seek care for severe, persistent abdominal pain.
- Diabetic retinopathy complications — rapid glucose improvement can transiently worsen existing retinopathy; patients with a history should be monitored.
- Hypoglycemia — low on its own, but elevated when combined with insulin or sulfonylureas, which may need dose reduction.
- Acute kidney injury — usually from dehydration driven by vomiting/diarrhea; stay hydrated.
- Gallbladder disease — including gallstones and cholecystitis.
- Severe gastrointestinal disease and concerns about retained gastric contents during anesthesia (delayed gastric emptying).
Semaglutide is not recommended during pregnancy, and the manufacturer advises discontinuing it at least 2 months before a planned pregnancy because of the long half-life.
Interactions
Because Ozempic slows gastric emptying, it can affect the absorption of oral medications taken at the same time; clinically the most-watched interactions are with insulin and sulfonylureas (hypoglycemia risk). Anyone on multiple medications should review the regimen with a prescriber or pharmacist.
Who is Ozempic for — and who should skip it?
Best for: adults with type 2 diabetes, particularly those who also have established cardiovascular disease or chronic kidney disease, where Ozempic offers organ-protective benefits beyond glucose control. It is a strong fit for people who value once-weekly dosing and want a single drug that addresses sugar, weight, heart, and kidney risk together.
Should skip or use caution: anyone with a personal or family history of medullary thyroid cancer or MEN 2 (absolute contraindication); people with a history of pancreatitis; those with type 1 diabetes (not indicated); and anyone who is pregnant or planning pregnancy. People whose *only* goal is weight loss and who do not have diabetes are arguably better served by the on-label product, Wegovy, both clinically and for insurance coverage.
What does Ozempic cost?
Ozempic is expensive. The U.S. list price is roughly $1,000 per month before any discounts, and it is the same regardless of which dose strength you use (GoodRx; manufacturer). Few people pay full list price:
- Commercial insurance: with a copay savings card, eligible patients with private insurance that covers Ozempic may pay as little as $25 per fill. Coverage for diabetes is generally good; coverage for off-label weight loss is often denied.
- Cash/self-pay: Novo Nordisk has introduced reduced self-pay pricing through its NovoCare channel — around $499 per month for self-paying patients, with lower introductory pricing (roughly $199 per month) on the starter 0.25 mg and 0.5 mg doses for new patients for a limited period. Discount programs such as GoodRx can also lower cash costs, though prices typically remain several hundred dollars monthly.
- Medicare: historically did not cover drugs prescribed solely for weight loss, though coverage for diabetes and approved cardiovascular/kidney indications differs.
Verify current pricing directly, as manufacturer programs and list prices change frequently. The practical takeaway: cost and insurance coverage often determine real-world access more than clinical suitability does.
How does Ozempic compare to alternatives?
- Wegovy (semaglutide 2.4 mg): same molecule, higher dose, FDA-approved for chronic weight management and for cardiovascular risk reduction in adults with obesity/overweight. The correct choice if weight loss is the goal.
- Rybelsus (oral semaglutide): the daily pill form of the same molecule for type 2 diabetes — convenient for needle-averse patients, but with strict empty-stomach dosing rules and generally somewhat lower glucose-lowering at available doses.
- Mounjaro / Zepbound (tirzepatide): a dual GIP/GLP-1 agonist from Eli Lilly. In head-to-head data, tirzepatide tends to produce greater A1c reduction and greater weight loss than semaglutide; in SURMOUNT-5, tirzepatide 15 mg achieved about 20% weight loss versus about 14% for semaglutide 2.4 mg. Semaglutide, however, has the longer and more mature cardiovascular/kidney outcomes track record.
- Older GLP-1s (dulaglutide/Trulicity, liraglutide/Victoza): effective but generally less potent on glucose and weight than semaglutide.
- Compounded semaglutide: sold cheaply by many telehealth platforms. It is not FDA-approved and not reviewed for safety, quality, or potency (FDA), and with the diabetes-drug shortages resolved, the legal basis for mass compounding has narrowed sharply. Branded Ozempic's trial data does not automatically apply to a compounded copy.
The bottom line
For adults with type 2 diabetes, Ozempic is a genuinely top-tier, evidence-rich medication: meaningful A1c reduction, proven cardiovascular benefit (SUSTAIN-6), proven kidney protection (FLOW), and the convenience of once-weekly dosing. Its main downsides are cost, frequent (usually transient) GI side effects, the thyroid-tumor boxed warning, and contraindications that must be screened for.
The most important honesty check is the indication itself. Ozempic is a diabetes drug. If you have diabetes — especially with heart or kidney disease — it is one of the best-supported choices available. If you are healthy and simply want to lose weight, the on-label, higher-dose alternative (Wegovy) or tirzepatide (Zepbound) is the more appropriate, better-covered, and better-studied path. Either way, this is a prescription medication with real risks: the decision belongs with a qualified prescriber who knows your full history, not with a marketing claim.
*This article is independent editorial analysis for general information and is not medical advice. HealthVetted accepts no payment for placement and sells none of the products it reviews. Consult a licensed clinician before starting, stopping, or changing any medication.*
How it works
Ozempic's active ingredient, semaglutide, is a GLP-1 receptor agonist: it mimics glucagon-like peptide-1, a natural gut hormone released after eating. It prompts the pancreas to release more insulin when blood sugar is high, suppresses glucagon (a hormone that raises blood sugar), and slows stomach emptying. It also acts on appetite centers in the brain to reduce hunger and food intake, which is why many people eat less and lose some weight.
Active ingredient: Semaglutide
Effectiveness
Across the SUSTAIN clinical trial program, Ozempic lowered A1C by roughly 1.0 to 1.8 percentage points depending on dose and starting level, with average weight reductions of about 6 to 14 lb (roughly 2.5 to 6.5 kg) at the 0.5 mg and 1 mg doses, and more at 2 mg. In the SUSTAIN-6 cardiovascular outcomes trial (3,297 patients with type 2 diabetes at high cardiovascular risk, published in NEJM in 2016), semaglutide reduced the primary composite of cardiovascular death, nonfatal heart attack, or nonfatal stroke by 26% versus placebo (6.6% vs 8.9%; hazard ratio 0.74, 95% CI 0.58 to 0.95). That composite benefit was driven mainly by a significant drop in nonfatal stroke; reductions in nonfatal heart attack and cardiovascular death individually were not statistically significant, and the trial notably found a higher rate of diabetic retinopathy complications in the semaglutide group. SUSTAIN-6 was designed as a safety (non-inferiority) trial that went on to show superiority on the composite. The separate 2024 FLOW trial showed a 24% reduction in a combined kidney-and-cardiovascular outcome, supporting the 2025 chronic kidney disease indication.
What to expect over time
A realistic timeline of what Ozempic users typically experience. Individual results vary; this is educational, not medical advice.
- Weeks 1-4 (starter dose)
You begin at 0.25 mg once weekly. This is a tolerability dose, not a treatment dose, meant to let your body adjust. Nausea, and sometimes diarrhea or constipation, often appear in the first 1-2 days after an injection and tend to be worst this month. Blood-sugar or weight changes are usually minimal so far.
- Weeks 5-8 (first therapeutic dose)
Your prescriber typically raises the dose to 0.5 mg weekly. Semaglutide reaches steady levels in the blood around 4-5 weeks, so this is when most people start noticing reduced appetite and early blood-sugar improvement. A brief return of nausea is common after each dose increase, then usually settles.
- Weeks 9-16 (continued titration)
If more blood-sugar control is needed, the dose may step up to 1 mg (and later to a 2 mg maximum), each increase spaced about 4 weeks apart. For most people GI side effects have faded by roughly weeks 6-8. Appetite suppression and gradual weight change are often more noticeable, though responses vary widely.
- Around week 30
This is when pivotal trials measured the main effect: in SUSTAIN 1, about 73% of people on 0.5 mg reached an A1C of 7% or under by 30 weeks. Expect your clinician to recheck A1C and weight around this point. Note: Ozempic is FDA-approved for type 2 diabetes; any weight loss is a secondary effect and not guaranteed.
- Maintenance (ongoing, indefinite)
Once you reach an effective dose, you stay on a once-weekly injection long term. Benefits to blood sugar and weight generally persist only while you keep taking it; trials show effects can diminish after stopping. Ongoing follow-up monitors A1C, side effects, and dose adjustments. Individual results vary.
Side effects
The most common side effects (reported in at least 5% of patients) are gastrointestinal: nausea (about 16-20%), vomiting, diarrhea, abdominal pain, and constipation. These are usually worst early on or after a dose increase and often ease over time; eating smaller, lower-fat meals can help. Serious but less common risks include pancreatitis (severe, persistent abdominal pain), gallbladder problems, acute kidney injury from dehydration, low blood sugar (especially when combined with insulin or sulfonylureas), worsening diabetic retinopathy, and allergic reactions. Ozempic carries an FDA boxed warning because semaglutide caused thyroid C-cell tumors in rodents; whether it does so in humans is unknown, but it is contraindicated in people with a personal or family history of medullary thyroid cancer or MEN 2. Tell your doctor about any persistent abdominal pain, vision changes, or signs of an allergic reaction.
Safety: who should avoid it & interactions
- ✕Personal or family history of medullary thyroid carcinoma (MTC). Ozempic is contraindicated in these patients (FDA Boxed Warning / Section 4). Semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors in rodents; human relevance is undetermined.
- ✕Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Ozempic is contraindicated in patients with MEN 2 (FDA Boxed Warning / Section 4).
- ✕Prior serious hypersensitivity reaction to semaglutide or to any of the excipients in Ozempic. Serious reactions including anaphylaxis and angioedema have been reported (FDA Section 4).
- ✕Not a substitute for insulin and not indicated in type 1 diabetes mellitus; semaglutide has not been studied and should not be used to treat type 1 diabetes or diabetic ketoacidosis (FDA label / StatPearls). Note: this is a limitation of use rather than a labeled absolute contraindication.
- ✕Pregnancy: not an absolute FDA contraindication but should be discontinued/avoided. Animal reproduction studies show potential fetal harm; the label advises use during pregnancy only if potential benefit justifies the potential risk, and Ozempic should be discontinued at least 2 months before a planned pregnancy due to its long half-life.
- MajorInsulin (e.g., insulin glargine, insulin aspart): Concomitant use may increase the risk of hypoglycemia, including severe hypoglycemia. When initiating Ozempic, consider reducing the dose of concomitantly administered insulin; monitor blood glucose and educate patients on signs/symptoms of hypoglycemia. (FDA label (Ozempic PI Sections 5.5 and 7.1))
- MajorInsulin secretagogues / sulfonylureas (e.g., glipizide, glyburide, glimepiride): Concomitant use may increase the risk of hypoglycemia, including severe hypoglycemia. When initiating Ozempic, consider reducing the dose of the sulfonylurea or other insulin secretagogue and monitor blood glucose. (FDA label (Ozempic PI Sections 5.5 and 7.1))
- MajorOther GLP-1 receptor agonists or GLP-1/GIP agonists (e.g., liraglutide, dulaglutide, tirzepatide): Concurrent use with another GLP-1 receptor agonist is not recommended; overlapping mechanisms increase risk of GI adverse effects without added benefit. Do not co-administer. (StatPearls (semaglutide); class guidance)
- ModerateOral medications generally (delayed gastric emptying): Semaglutide delays gastric emptying and may impact absorption of concomitantly administered oral medications. In clinical pharmacology trials it did not affect oral drug absorption to a clinically relevant degree; nonetheless, caution should be exercised when oral medications are co-administered. (FDA label (Ozempic PI Section 7.2))
- ModerateOral medications with narrow therapeutic index (e.g., warfarin, levothyroxine, certain anticonvulsants): Because of delayed gastric emptying and potential altered absorption, increased clinical or laboratory monitoring is reasonable when these drugs are co-administered (e.g., INR monitoring with warfarin, thyroid function monitoring with levothyroxine). (FDA label (Section 7.2) / clinical pharmacology guidance)
- ModerateDrugs that independently delay gastric emptying or carry GI/dehydration risk (e.g., opioids, anticholinergics; diuretics with vomiting/diarrhea): Additive delayed gastric emptying may worsen GI adverse effects; volume depletion from semaglutide-related vomiting/diarrhea combined with diuretics, ACE inhibitors, ARBs, or NSAIDs can raise risk of acute kidney injury. Monitor renal function and hydration, especially during dose escalation. (FDA label (Warnings/Precautions) / StatPearls)
Sourced from FDA labeling and clinical references; not exhaustive and not a substitute for your prescriber or pharmacist. Always disclose every medication and supplement you take.
Cost
Starts at $349/mo from Novo Nordisk.
As of September 2026, NovoCare Pharmacy sells Ozempic to self-pay patients for $349/month (0.25, 0.5 or 1 mg pens) and $499/month (2 mg), and new patients pay $199/month for their first two fills of 0.25 mg or 0.5 mg through December 31, 2026. The Ozempic pill costs $149–$299/month depending on dose. The list price is roughly $1,000 per pen package — close to what an uninsured patient pays at a regular pharmacy counter without these programs. Commercially insured patients may pay less with the manufacturer savings card (caps apply; not available with government insurance). Medicare and Medicaid typically cover Ozempic for type 2 diabetes but not for weight loss. Confirm pricing and coverage before starting.
NovoCare Pharmacy self-pay (checked Sept 15, 2026): $349/month for 0.25, 0.5 or 1 mg pens; $499/month for 2 mg. New patients pay $199/month for the first two fills of 0.25 or 0.5 mg (through Dec 31, 2026). Ozempic pill: $149–$299/month by dose.
Prices current as of May 29, 2026 and exclude promo codes; cash-pay and channel pricing change frequently — confirm with the pharmacy or provider.
Is it worth it?
If you have type 2 diabetes, especially with heart or kidney disease, Ozempic is a strong, evidence-backed choice with cardiovascular and renal benefits few diabetes drugs can match. If your only goal is weight loss, Wegovy is the on-label sibling. Either way, plan for GI side effects, weekly injections, and a frank conversation about cost and insurance. Only a licensed clinician can decide whether Ozempic is right for you; this is general information, not medical advice.
Frequently asked questions
Is Ozempic approved for weight loss?
No. Ozempic is FDA-approved for type 2 diabetes, for reducing cardiovascular risk in those with heart disease, and for slowing chronic kidney disease in diabetes, not for weight loss. Its sister drug Wegovy contains the same medication (semaglutide) at a higher dose and is FDA-approved for chronic weight management.
How much weight can you lose on Ozempic?
In type 2 diabetes trials, people lost roughly 6 to 14 lb on average over about 30 to 56 weeks, depending on the dose. Weight loss is a secondary effect of Ozempic, not its primary purpose, and tends to be greater with the higher-dose, weight-loss-specific drug Wegovy. Individual results vary.
What is the difference between Ozempic and Wegovy?
Both contain the same active drug, semaglutide. Ozempic is FDA-approved for type 2 diabetes (plus cardiovascular and kidney risk reduction) and tops out at 2 mg weekly; Wegovy is FDA-approved for weight management and is dosed higher (up to 2.4 mg weekly), generally producing more weight loss.
How long does Ozempic take to work?
Blood-sugar effects begin within the first few weeks, but it typically takes about 4 to 8 weeks at an effective dose (0.5 mg or higher) to see a meaningful A1C improvement. Weight changes usually appear gradually over several months.
What are the most common side effects of Ozempic?
The most common side effects are gastrointestinal: nausea (about 16-20% of patients), vomiting, diarrhea, abdominal pain, and constipation. They are usually worst when starting Ozempic or increasing the dose and often improve over time. Tell your doctor about severe or persistent symptoms.
Who should not take Ozempic?
Avoid Ozempic if you or a family member has had medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or if you have had a serious allergic reaction to semaglutide. It is also not for type 1 diabetes. Use caution with a history of pancreatitis, gallbladder disease, or diabetic retinopathy, and discuss pregnancy with your doctor.
How much does Ozempic cost without insurance in 2026?
As of 2026, the list price is about $935 per month, and retail cash prices run roughly $935 to $969 per month. Novo Nordisk's NovoCare self-pay program offers lower cash prices (about $349/month for most pens, $499/month for the 2 mg pen), and commercially insured patients may pay as little as $25/month with the savings card, though that lowest price is capped and time-limited.
What happens if you stop taking Ozempic?
Blood sugar usually rises again and much of any weight lost tends to return, because the drug's appetite and metabolic effects are active only while you take it. Do not stop Ozempic on your own; discuss any changes with your doctor first.
Do you have to take Ozempic forever?
For most people, Ozempic is a long-term therapy. Type 2 diabetes is a chronic condition, and the blood-sugar, weight, and cardiovascular benefits generally persist only while treatment continues. Your doctor can advise on how long you should stay on it.
Sources
- OZEMPIC (semaglutide) injection, for subcutaneous use — Highlights of Prescribing Information (FDA label, 2025) — U.S. Food and Drug Administration (Drugs@FDA) (2025)
- DailyMed — OZEMPIC (semaglutide) injection, solution (FDA-approved label) — U.S. National Library of Medicine, DailyMed (2024)
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) — New England Journal of Medicine (2016)
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) — PubMed record — PubMed (New England Journal of Medicine) (2016)
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial) — New England Journal of Medicine (2023)
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW trial) — New England Journal of Medicine (2024)
- Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a phase 3a trial — The Lancet Diabetes & Endocrinology (2017)
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial — The Lancet Diabetes & Endocrinology (2018)
- Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a phase 3B trial — The Lancet Diabetes & Endocrinology (2021)
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 — Diabetes Care (American Diabetes Association) (2025)
- Semaglutide — StatPearls (drug class, mechanism, pharmacology) — StatPearls, NCBI Bookshelf (NIH) (2024)
- Semaglutide Injection — MedlinePlus Drug Information — MedlinePlus, U.S. National Library of Medicine (2024)
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — U.S. Food and Drug Administration (2025)
- Novo Nordisk Receives FDA Approval of OZEMPIC (semaglutide) Injection for the Treatment of Adults with Type 2 Diabetes — Novo Nordisk (PR Newswire) (2017)
- Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6 — Frontiers in Cardiovascular Medicine (PMC) (2021)
- Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis — Frontiers in Pharmacology (2025)
Ready to try Ozempic?
Check eligibility & price — from $349/mo- May be covered by insurance
Affiliate link — we may earn a commission at no extra cost to you, and it never changes our rankings or score. Disclosure
Related guides
Ways to save on Ozempic
Legitimate ways to lower your cost. We don’t sell Ozempic — this is independent guidance, not medical or financial advice. Confirm current terms with the program and your clinician.
- Manufacturer savings program
The maker of Ozempic runs a commercial-insurance savings program that can lower your copay. See the official Ozempic savings page → Eligibility rules apply and these programs typically exclude government insurance (Medicare/Medicaid).
- Patient assistance programs (PAPs)
If you’re uninsured or low-income, free or reduced-cost medication may be available through patient assistance programs. Search MedicineAssistanceTool (PhRMA) and NeedyMeds.
- Ask about a 90-day supply
Filling a 90-day supply instead of monthly often lowers the per-month cost and cuts pharmacy trips. Ask your prescriber and pharmacy whether it’s an option for you.
- Compare lower-cost alternatives
A different formulation or product may cost less for a similar result. Compounded GLP-1 · Supplements vs GLP-1.
How Ozempic compares
Same-category options, scored on the same six-axis rubric. Higher is better.